p53: prospects for cancer gene therapy

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• The p53 gene (TP53) initially identified as an oncogene, was later recognized for its tumor-suppressive functions.
• Functional inactivation of p53 is a frequent event in human cancers, contributing to tumor development and progression.
• Loss of p53 function is linked to radioresistance and chemoresistance, often through apoptosis-resistant phenotypes.

Purpose of the Study:

• To review current p53-based cancer therapeutic strategies.
• To discuss the biological questions that need clarification for improved p53-based therapies.
• To highlight the potential of targeting p53 for cancer treatment.

Main Methods:

• Review of in vitro and in vivo experimental studies.
• Analysis of transduction experiments demonstrating exogenous TP53 overexpression.
• Discussion of therapeutic approaches based on experimental findings.

Main Results:

• Wild-type p53 suppresses cell proliferation and transformation.
• Exogenous TP53 overexpression can induce growth arrest, apoptosis, or differentiation, suppressing the transformed phenotype.
• Inactivation of TP53 contributes to radioresistant and chemoresistant tumors.

Conclusions:

• p53 is a crucial tumor suppressor, essential for maintaining the non-tumorigenic phenotype.
• Restoring or exploiting p53 function presents a viable therapeutic avenue for various human cancers.
• Further research is needed to optimize p53-based cancer therapies.